Analyst Price Targets — FATE
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 6, 2025 11:51 am | — | Stifel Nicolaus | $3.00 | $1.04 | TheFly | Fate Therapeutics price target lowered to $3 from $5 at Stifel |
| November 13, 2024 1:53 pm | Etzer Darout | BMO Capital | $5.00 | $3.37 | StreetInsider | Fate Therapeutics (FATE) PT Lowered to $5 at BMO Capital |
| August 14, 2024 8:37 am | Benjamin Burnett | Stifel Nicolaus | $5.00 | $3.27 | StreetInsider | Fate Therapeutics (FATE) PT Lowered to $5 at Stifel |
| June 17, 2024 3:50 am | Edward Tenthoff | Piper Sandler | $6.00 | $3.61 | StreetInsider | Piper Sandler Upgrades Fate Therapeutics (FATE) to Overweight |
| May 16, 2024 6:44 am | Debjit Chattopadhyay | H.C. Wainwright | $5.00 | $4.24 | StreetInsider | Fate Therapeutics (FATE) PT Lowered to $5 at H.C. Wainwright |
| May 10, 2024 8:14 am | Edward Tenthoff | Piper Sandler | $4.00 | $3.88 | StreetInsider | Fate Therapeutics (FATE) PT Lowered to $4 at Piper Sandler |
| May 10, 2024 7:55 am | Etzer Darout | BMO Capital | $6.00 | $3.87 | StreetInsider | Fate Therapeutics (FATE) PT Lowered to $6 at BMO Capital |
| May 10, 2024 7:28 am | Bill Maughan | Canaccord Genuity | $9.00 | $3.90 | TheFly | Fate Therapeutics price target lowered to $9 from $11 at Canaccord |
| January 9, 2023 8:08 am | — | Goldman Sachs | $4.00 | $4.40 | Benzinga | Goldman Sachs Maintains Sell on Fate Therapeutics, Lowers Price Target to $4 |
| January 6, 2023 9:26 am | — | Morgan Stanley | $8.00 | $4.22 | Benzinga | Morgan Stanley Maintains Equal-Weight on Fate Therapeutics, Lowers Price Target to $8 |
Latest News for FATE
Fate Therapeutics (NASDAQ: FATE) used a presentation at the Needham Healthcare Conference to outline its strategy for developing "off-the-shelf" CAR T-cell therapies, highlighting clinical progress in autoimmune disease with FT819 and early proof-of-concept signals in solid tumors with FT836. President and CEO Bob Valamehr was joined by Chief Financial Officer Kamal Adawi. Positioning CAR T as
SAN DIEGO, April 02, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on April 1, 2026, the Company granted restricted stock units (RSUs) representing 7,260 shares of…
/PRNewswire/ -- USANewsGroup.com News Commentary - The global cell therapy manufacturing market is hitting a pivotal inflection point. It's projected to
Fate Therapeutics, Inc. (NASDAQ: FATE - Get Free Report) has earned an average rating of "Hold" from the eight ratings firms that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, four have given a hold recommendation and three have given a buy recommendation to the company. The
SAN DIEGO, March 04, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on March 2, 2026, the Company granted restricted stock units (RSUs) representing 50,700 shares of…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for FATE.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.